221 related articles for article (PubMed ID: 16053696)
1. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
[TBL] [Abstract][Full Text] [Related]
2. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
4. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
[TBL] [Abstract][Full Text] [Related]
5. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
Andreansky S; He B; van Cott J; McGhee J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Gene Ther; 1998 Jan; 5(1):121-30. PubMed ID: 9536273
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.
Markert JM; Cody JJ; Parker JN; Coleman JM; Price KH; Kern ER; Quenelle DC; Lakeman AD; Schoeb TR; Palmer CA; Cartner SC; Gillespie GY; Whitley RJ
J Virol; 2012 May; 86(9):5304-13. PubMed ID: 22379082
[TBL] [Abstract][Full Text] [Related]
7. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
8. A syngeneic mouse glioma model for study of glioblastoma therapy.
Weiner NE; Pyles RB; Chalk CL; Balko MG; Miller MA; Dyer CA; Warnick RE; Parysek LM
J Neuropathol Exp Neurol; 1999 Jan; 58(1):54-60. PubMed ID: 10068314
[TBL] [Abstract][Full Text] [Related]
9. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
[TBL] [Abstract][Full Text] [Related]
10. Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir.
Namba H; Tagawa M; Miyagawa T; Iwadate Y; Sakiyama S
Cancer Gene Ther; 2000 Jun; 7(6):947-53. PubMed ID: 10880027
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
[TBL] [Abstract][Full Text] [Related]
12. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.
Andreansky SS; He B; Gillespie GY; Soroceanu L; Markert J; Chou J; Roizman B; Whitley RJ
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11313-8. PubMed ID: 8876132
[TBL] [Abstract][Full Text] [Related]
13. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
14. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
[TBL] [Abstract][Full Text] [Related]
15. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.
Parker JN; Meleth S; Hughes KB; Gillespie GY; Whitley RJ; Markert JM
Cancer Gene Ther; 2005 Apr; 12(4):359-68. PubMed ID: 15678154
[TBL] [Abstract][Full Text] [Related]
16. HSV1716 persistence in primary human glioma cells in vitro.
Harland J; Papanastassiou V; Brown SM
Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered human herpes simplex virus in the treatment of brain tumours.
Markert JM; Parker JN; Gillespie GY; Whitley RJ
Herpes; 2001 Mar; 8(1):17-22. PubMed ID: 11867012
[TBL] [Abstract][Full Text] [Related]
20. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
Chambers R; Gillespie GY; Soroceanu L; Andreansky S; Chatterjee S; Chou J; Roizman B; Whitley RJ
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1411-5. PubMed ID: 7877992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
